Guggenheim Capital LLC Purchases 22,986 Shares of Kenvue Inc. (NYSE:KVUE)

Guggenheim Capital LLC lifted its position in Kenvue Inc. (NYSE:KVUE) by 13.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 196,128 shares of the company’s stock after acquiring an additional 22,986 shares during the period. Guggenheim Capital LLC’s holdings in Kenvue were worth $4,187,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Norges Bank bought a new stake in Kenvue in the fourth quarter worth about $521,348,000. Franklin Resources Inc. lifted its stake in shares of Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after acquiring an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock valued at $2,085,070,000 after acquiring an additional 10,682,003 shares during the period. Boston Partners grew its position in Kenvue by 36.9% in the 4th quarter. Boston Partners now owns 23,595,963 shares of the company’s stock valued at $503,145,000 after acquiring an additional 6,366,097 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Kenvue in the fourth quarter worth $98,926,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Trading Up 3.0 %

KVUE opened at $23.42 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market cap of $44.93 billion, a price-to-earnings ratio of 44.19, a PEG ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The stock has a fifty day moving average price of $22.91 and a 200-day moving average price of $22.41.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.50%. Kenvue’s payout ratio is 154.72%.

Analyst Ratings Changes

KVUE has been the subject of a number of recent analyst reports. Canaccord Genuity Group boosted their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Evercore ISI started coverage on shares of Kenvue in a research report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price objective for the company. Citigroup raised their target price on shares of Kenvue from $21.00 to $22.00 and gave the stock a “neutral” rating in a research report on Monday, April 14th. Barclays lowered their price target on Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, April 14th. Finally, UBS Group lowered their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average target price of $24.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.